Loading
A phase 3 trial of Bel-sar in uveal melanoma, run by Aura Biosciences, active and no longer recruiting.
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma is a phase 3 interventional study registered as NCT06007690 by Aura Biosciences, with 108 participants enrolled, started 2023-12-06 and due to reach its primary completion in 2027-11-15. Interventions recorded: Bel-sar, Suprachoroidal Microinjector, Infrared Laser, Sham Infrared Laser and Sham Microinjector.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Aura Biosciences and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/